A Agilent Technologies Inc.

Agilent Announces High-Performance Cary 3500 Flexible UV-Vis System

(NYSE: A) today announced the latest addition to the Cary 3500 UV-Vis Series with the release of the . This new solution is a double-beam spectrophotometer with advanced photometric performance for diverse sample-type measurements with minimal sample preparation. The Cary 3500 UV-Vis Series can be deployed in regulated environments, specifically the pharma/biopharma industry.

The new Cary 3500 Flexible UV-Vis system offers a uniquely large sample compartment with a small footprint for analyzing a range of liquid samples and characterizing solid samples. The full Cary 3500 UV-Vis spectrophotometer series also includes a 10-year warranty xenon flash lamp, (for Cary 3500 instruments purchased from Agilent or participating partners), drastically reducing the frequency and cost of deuterium lamp replacement, and eliminating the daily warmup time.

Another key development is the enhancement of the . New calculations can now be saved and applied automatically to any method routinely used to reduce data processing time and calculation errors. It is accessible to new customers and existing users who want to upgrade to the latest software version. Additionally, the Cary 3500 UV-Vis spectrophotometer series, including the new UV-Vis Flexible module, can be deployed with the to help organizations achieve their data management and compliance goals.

“The Cary 3500 Flexible UV-Vis spectrophotometer is the next major step in a long history of UV-Vis innovation at Agilent,” said Geoff Winkett, vice president and general manager of Agilent’s Molecular Spectroscopy Division.

Winkett continued. “The series has been an incredible success since its introduction in 2018 and our customers—particularly those in the pharma and biopharma industries—have benefitted from the unique range of capabilities. This further strengthens our distinctive portfolio of integrated solutions under the Agilent OpenLab umbrella, from chromatography to mass spectroscopy, to UV-Vis spectroscopy.”

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global leader in the life sciences, diagnostics, and applied chemical markets, delivering insight and innovation that help our customers bring great science to life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.85 billion in fiscal 2022 and employs 18,000 people worldwide. Information about Agilent is available at . To receive the latest Agilent news, please subscribe to the Agilent . Follow Agilent on and .

EN
03/04/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Agilent Technologies Inc.

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

 PRESS RELEASE

Agilent xCELLigence RTCA Instrumentation Applied in Recent FDA Approva...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- (NYSE: A) is pleased to announce its role in supporting Autolus Therapeutics’ , a recently approved CAR T therapy. Agilent's advanced cell analysis instrumentation, specifically the technology, was applied in developing and validating AUCATZYL. The xCELLigence RTCA technology supported the development and implementation of the potency assay. By providing precise and reliable cell analysis solutions, Agilent assisted Autolus in achieving the high standards required for FDA approval. Dr. Xiaobo Wang, Vice President and General Manager of the Cell Functio...

 PRESS RELEASE

CORRECTING and REPLACING Agilent to Showcase Next-Generation Digital P...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- Please replace the release with the following corrected version due to multiple revisions to the fifth paragraph. The updated release reads: AGILENT TO SHOWCASE NEXT-GENERATION DIGITAL PATHOLOGY SOLUTIONS AT USCAP 2025 (NYSE: A) is excited to announce its participation at the upcoming , which will be held March 22-27, 2025, in Boston. At the conference, Agilent will highlight innovative digital pathology solutions designed to enhance diagnostic accuracy and efficiency. In pathology, Agilent offers comprehensive tissue diagnostic solutions for analyzi...

 PRESS RELEASE

Agilent Research Catalyst Award Presented to Columbia University for P...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- (NYSE: A) today announced that has received an Agilent Research Catalyst (ARC) Award on behalf of , an internationally recognized researcher and physician-scientist specializing in bone marrow transplant (BMT) and cancer cellular immunotherapy. Dr. Muranski is the Director of Cellular Immunotherapy Laboratory at Columbia University Irving Medical Center. He is also an Assistant Professor of Medicine at Columbia University Medical Center, a principal investigator at the Columbia Center for Translational Immunology (CCTI), and a member of the Herbert Irv...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch